HOB Biotech Group Corp Ltd
SSE:688656
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (63.4), the stock would be worth ¥31.9 (77% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 273.1 | ¥137.49 |
0%
|
| 3-Year Average | 63.4 | ¥31.9 |
-77%
|
| 5-Year Average | 52.9 | ¥26.65 |
-81%
|
| Industry Average | 41.6 | ¥20.93 |
-85%
|
| Country Average | 28.8 | ¥14.51 |
-89%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
¥8.7B
|
/ |
Oct 2025
¥31.5m
|
= |
|
|
¥8.7B
|
/ |
Dec 2025
¥157.6m
|
= |
|
|
¥8.7B
|
/ |
Dec 2026
¥185.8m
|
= |
|
|
¥8.7B
|
/ |
Dec 2027
¥211.1m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
H
|
HOB Biotech Group Corp Ltd
SSE:688656
|
8.6B CNY | 273.1 | 236.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
355.3B USD | 14.1 | 84.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.5B USD | 14.1 | 24.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
164.9B USD | 12.2 | 19.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.2B USD | 21 | 28 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 13.4 | 18 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR | 41.5 | 38.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.3B AUD | 10.4 | 30.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
HOB Biotech Group Corp Ltd
Glance View
HOB Biotech Group Corp. Ltd. engages in the research and development, production, and sale of in-vitro diagnostic reagents. The company is headquartered in Suzhou, Jiangsu and currently employs 431 full-time employees. The company went IPO on 2021-01-13. The firm provides two categories of products: allergy testing products and self-immune testing products. Its detection techniques include qualitative detection techniques such as enzyme-linked immunosorbent assay, and quantitative detection techniques such as enzyme-linked immunoassay capture method and nano-magnetic particle chemiluminescence method. The brands of allergy testing products include Oboke, Fubok, Shibok and Shibok Plus. The self-immune testing product brands include Norbok and Nabok. The company is also engaged in the provision of reagent supporting testing instruments and others. The firm conducts its businesses in the domestic market.
